INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA

被引：0
|
作者：
Porter, J. [1 ]
Cappellini, M. D. [2 ]
Origa, R. [3 ]
Forni, G. L. [4 ]
Laadem, A. [5 ]
Galacteros, F. [6 ]
Voskaridou, E. [7 ]
Miteva, D. [5 ]
Sung, V. [5 ]
Chopra, R. [5 ]
Arlet, J. B. [8 ]
Ribeil, J. A. [8 ]
Klesczewski, K. [5 ]
Attie, K. [9 ]
Garbowski, M. [1 ]
Graziadei, G. [2 ]
Balocco, M. [4 ]
Hermine, O. [8 ]
机构：
[1] UCL, London, England
[2] Univ Milan, Ca Granda Fdn IRCCS, Milan, Italy
[3] Univ Cagliari, Osped Reg Microcitemie, Cagliari, Italy
[4] Ente Osped Osped Galliera, Genoa, Italy
[5] Celgene Corp, Summit, NJ USA
[6] Grp Hosp Henri Mondor, Creteil, France
[7] Laikon Gen Hosp, Athens, Greece
[8] Hop Necker Enfants Malad, Inst Imagine, Paris, France
[9] Acceleron Pharma, Cambridge, MA 02139 USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S662
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [1] A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results
    Cappellini, Maria-Domenica
    Porter, John
    Origa, Raffaella
    Forni, Gian Luca
    Laadem, Adberrahmane
    Galacteros, Frederic
    Miteva, Dimana
    Sung, Victoria
    Chopra, Rajesh
    Arlet, Jean-Benoit
    Ribeil, Jean-Antoine
    Klesczewski, Kenneth
    Attie, Kenneth
    Garbowski, Maciej
    Hermine, Olivier
    BLOOD, 2013, 122 (21)
  • [2] INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA
    Cappellini, M. D.
    Porter, J.
    Origa, R.
    Forni, G. L.
    Voskaridou, E.
    Taher, A. T.
    Laadem, A.
    Galacteros, F.
    Miteva, D.
    Sung, V.
    Chopra, R.
    Arlet, J. B.
    Ribeil, J. A.
    Zou, J.
    Chen, N.
    Attie, K. M.
    Garbowski, M.
    Graziadei, G.
    Balocco, M.
    Hermine, O.
    HAEMATOLOGICA, 2015, 100 : 17 - 18
  • [3] A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ANEMIA REQUIRING TRANSFUSION
    Komrokji, R.
    Garcia-Manero, G.
    Ades, L.
    Laadem, A.
    Vo, B.
    Prebet, T.
    Stamatoullas, A.
    Boyd, T.
    Delaunay, J.
    Steensma, D. P.
    Sekeres, M. A.
    Beyne-Rauzy, O.
    Zou, J.
    Attie, K. M.
    Sherman, M. L.
    Fenaux, P.
    List, A. F.
    HAEMATOLOGICA, 2015, 100 : 192 - 192
  • [4] Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study
    Cappellini, Maria Domenica
    Porter, John
    Origa, Raffaella
    Forni, Gian Luca
    Voskaridou, Ersi
    Galacteros, Frederic
    Taher, Ali T.
    Arlet, Jean-Benoit
    Ribeil, Jean-Antoine
    Garbowski, Maciej
    Graziadei, Giovanna
    Brouzes, Chantal
    Semeraro, Michaela
    Laadem, Abderrahmane
    Miteva, Dimana
    Zou, Jun
    Sung, Victoria
    Zinger, Tatiana
    Attie, Kenneth M.
    Hermine, Olivier
    HAEMATOLOGICA, 2019, 104 (03) : 477 - 484
  • [5] An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Ades, Lionel
    Laadem, Abderrahmane
    Vo, Bond
    Prebet, Thomas
    Stamatoullas, Aspasia
    Boyd, Thomas
    Delaunay, Jacques
    Steensma, David P.
    Sekeres, Mikkael A.
    Beyne-Rauzy, Odile
    Zou, Jun
    Attie, Kenneth
    Sherman, Matthew L.
    Fenaux, Pierre
    List, Alan F.
    BLOOD, 2014, 124 (21)
  • [6] Safety, tolerability, and preliminary efficacy of tinodasertib as a monotherapy or in combination with pembrolizumab or irinotecan in metastatic colorectal cancer: Interim results from a phase II open-label, dose-finding, run-in and cohort expansion study.
    Matos, Marco
    Kannourakis, George
    Aghmesheh, Morteza
    Mendis, Shehara Ramyalini
    Mahon, Kate
    Dave, Harish P.
    Barde, Prajak J.
    Schwedat, Anke
    Patava, John
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 183 - 183
  • [7] Safety and tolerability of bexicaserin in adolescents and adults with developmental and epileptic encephalopathies: Interim results of the phase 1b/2a PACIFIC Study Open-Label Extension (OLE)
    McLin, D.
    Orevillo, C.
    Le, M.
    Kaye, R.
    EPILEPSIA, 2024, 65 : 449 - 449
  • [8] PULSAR Study Open-Label Extension: Interim Results from a Phase 2 Study of the Efficacy and Safety of Sotatercept When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
    Badesch, D. B.
    Gibbs, S.
    Gomberg-Maitland, M.
    Hoeper, M. M.
    McLaughlin, V. V.
    Preston, I
    Souza, R.
    Waxman, A. B.
    Manimaran, S.
    Barnes, J.
    Pena, J. de Oliveira
    Humbert, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)
    Badesch, David
    Gibbs, Simon
    Gomberg-Maitland, Mardi
    Hoeper, Marius
    Mclaughlin, Vallerie
    Preston, Ioana
    Souza, Rogerio
    Waxman, Aaron
    Manimaran, Solaiappan
    Barnes, Jennifer
    Pena, Janethe De Oliveira
    Humbert, Marc
    Hoeper, Marius M.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] AN OPEN-LABEL PHASE 2, DOSE-FINDING STUDY OF THE SAFETY AND EFFICACY OF RUSFERTIDE (PTG-300), A HEPCIDIN MIMETIC, IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS
    Kowdley, Kris V.
    Modi, Nishit
    Valone, Frank
    Priego, Victor
    Cole, Frank
    Pouzar, Joe
    Gupta, Suneel
    HEPATOLOGY, 2021, 74 : 24A - 25A
12345